# Astec Lifesciences share price today (Astec Lifesciences Ltd, NSE: ASTEC)

> Astec Lifesciences share price today: ₹555.95 at the NSE close on 3 November 2026, down 15.8% in a year. Astec Lifesciences (NSE: ASTEC) is worth ₹1,238 crore, trades at a P/E of 110.6 and has closed between ₹543.00 and ₹837.90 over the past 52 weeks. > Astec Lifesciences Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ASTEC · Pesticides/Agrochemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/astec-lifesciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹555.95 (−15.8% in a year)
- P/E: 110.6× (higher than 94% of the last 7.4 years)
- Revenue (Sep 2026): ₹72.0 Cr (−2.7% on a year ago)
- Profit (Sep 2026): −₹37.0 Cr
- Operating margin: −27.0% (−18.0 points on a year ago)
- ROCE: −5%, FY26
- ROIC: −7.0%, against a 12.0% cost of capital: −19.0 points
- Profit that came in as cash: 50%, last 3 years

The main question: promoters moved +5.2 percentage points over 8 quarters while the business went the other way. ## What is the Astec Lifesciences share price today? Astec Lifesciences Ltd's share price was ₹555.95 at the close on 3 November 2026. It has been falling for 12 weeks. That is 19.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹543 and ₹838, and at that close it sat 4% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 11 years the share price moved +182% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Astec Lifesciences this quarter? Two changes stood out: profit fell in the September 2026 quarter and lowest operating margin in 9 quarters. 1. Profit fell in the September 2026 quarter Profit was ₹-37 crore, -54.2% on a year earlier (₹-24 crore), after 5 quarters of growth. 2. Lowest operating margin in 9 quarters Operating margin was -27% in the September 2026 quarter, against -9% a year earlier. ## What are Astec Lifesciences' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Astec Lifesciences reported revenue of ₹72.0 crore, down 2.7% from ₹74.0 crore a year earlier, and a loss of ₹37.0 crore. ### Astec Lifesciences results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹72.0 crore | ₹74.0 crore | −2.7% |
| Profit | loss of ₹37.0 crore | loss of ₹24.0 crore | n/a |
| Earnings per share | ₹−16.79 | ₹−10.96 | n/a |
| Operating margin | −27.0% | −9.0% | −18.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Astec Lifesciences share price history? Astec Lifesciences closed at ₹555.95 on 3 November 2026, down 15.8% from ₹660.05 a year earlier (31 October 2025) and down 57.1% over five years. Its highest weekly close since March 2016 was ₹2,157.55 on 4 November 2022. ### Astec Lifesciences share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹664.30 | −16.3% |
| 1 month ago · 1 Oct 2026 | ₹708.80 | −21.6% |
| 6 months ago · 30 Apr 2026 | ₹694.70 | −20.0% |
| 1 year ago · 31 Oct 2025 | ₹660.05 | −15.8% |
| 3 years ago · 3 Nov 2023 | ₹1,262.30 | −56.0% |
| 5 years ago · 4 Nov 2021 | ₹1,296.09 | −57.1% |
| 10 years ago · 4 Nov 2016 | ₹606.61 | −8.4% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹196.80 | +182.5% |
| Highest weekly close since March 2016 · 4 Nov 2022 | ₹2,157.55 | −74.2% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹189.05 | +194.1% |
| 52-week high (weekly close) · 28 Nov 2025 | ₹837.90 | −33.6% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹543.00 | +2.4% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Astec Lifesciences? 3 Nov 2026: Astec Lifesciences closed at ₹555.95, down 16.3% on the week and down 21.6% on the month. Results for July to September 2026: Revenue down 2.7% on a year earlier. ## What dividend does Astec Lifesciences pay? Astec Lifesciences paid no dividend in the 12 months to 4 November 2026. The last was a dividend of ₹1.50 a share, ex-date 21 July 2023. ### Astec Lifesciences dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 21 Jul 2023 | ₹1.50 | Dividend |
| 19 Jul 2022 | ₹1.50 | Dividend |
| 22 Jul 2021 | ₹1.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 3 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Astec Lifesciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 9 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Astec Lifesciences on? Astec Lifesciences is not on any of our India lists this week. ## Is Astec Lifesciences profitable? Astec Lifesciences Ltd posted a net loss of ₹37.0 Cr in the Sep 2026 quarter. The full FY26 year was a loss of ₹81.0 Cr. That loss is 51.4% of the quarter's revenue. The same quarter a year earlier lost ₹24.0 Cr. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Astec Lifesciences make, and is it growing? Astec Lifesciences Ltd reported ₹72.0 Cr of revenue in the Sep 2026 quarter, −2.7% on the same quarter a year earlier. Over 10 years it has grown 6.8% a year on average. The last full year, FY26, came in at ₹448 Cr. The last four reported quarters add to ₹440 Cr. FY26 revenue was ₹448 Cr, +17.6% on the year before. Recent pace: the last four quarters grew +13.8% on average, against 6.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +16.1%, against +8.6% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Astec Lifesciences keep? Astec Lifesciences Ltd's operating margin was −27.0% in the Sep 2026 quarter, 18.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between −17.0% and 23.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −18.4 percentage points on the year while gross margin changed −16.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Astec Lifesciences' profit turning into cash? Over the last 3 years, 50% of Astec Lifesciences Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used ₹81.0 Cr of cash, against −₹81.0 Cr of profit. After ₹4.0 Cr of spending on assets, free cash was −₹85.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 50% of profit came in as cash: the cash cycle got 163 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 163 days longer. The next section looks at where the cash is stuck. ## Where does Astec Lifesciences' cash go? Astec Lifesciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 263 days in FY26, up from 100 days in FY21. It spent ₹159 Cr on assets over the last 3 years. Customers take 202 days to pay, and stock sits for 169 days on average. At FY26 sales of ₹448 Cr, each day of that cycle ties up about ₹1.2 Cr, so roughly ₹323 Cr is tied up in the business at any time. FY26: customers took 202 days to pay and stock sat for 169 days, about 5.6 months of sales sitting as stock, for a full cycle of 263 days, longer than FY21's 100. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 169 days. Customers pay about 202 days after that. Suppliers are paid at 107 days. Together that makes the 263-day cycle. Spending on assets: ₹159 Cr over the last 3 years, against ₹125 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹20.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Astec Lifesciences' P/E ratio, and how does it compare with its own history? Astec Lifesciences Ltd's P/E is 110.6×, near the high end of its own history: higher than 94% of past readings. Its usual P/E (the middle reading) is 46.4×, over 7.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 5 years the price moved −15.6% a year; about −4.3% a year came from earnings growth and about −11.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Astec Lifesciences business getting better or worse? Astec Lifesciences Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Astec Lifesciences earn on its capital? Astec Lifesciences Ltd earned a ROCE of −5% in FY26. That is up from a low of −13% in FY25. Its return on capital used (ROIC) is 19.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −18.1% net margin and 0.48× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −18.1% net margin × 0.48× asset turnover × 2.42× leverage (assets divided by equity) ≈ −21.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −7.0% − 12.0% = −19.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Astec Lifesciences have too much debt? Astec Lifesciences Ltd has total debt of ₹331 Cr against shareholder equity of ₹335 Cr as of Sep 2026, so its debt is 0.99× its equity. Year by year, that ratio went from 0.70 in FY22 to 1.15 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Astec Lifesciences shareholding pattern? Promoters raised their stake in Astec Lifesciences Ltd by 5.2 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 72.0% of the company. Domestic institutions moved −1.2 points over the same period, to 3.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +5.2 points over 8 quarters, to 72.0%; Domestic institutions: −1.2 points over 8 quarters, to 3.3%; Foreign institutions: −0.5 points over 8 quarters, to 0.0%. Why the owners changed: promoters drove it (+5.2 points), with the other side taken by domestic institutions (−1.2 points). They raised their stake step by step. ## How far is Astec Lifesciences from balance-sheet trouble? For Astec Lifesciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Astec Lifesciences rank in its industry? 32.7 out of 100, rank 24 of 25 in Pesticides/Agrochemicals, with 71% of the evidence available. Astec Lifesciences Ltd scores 32.7 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 24. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 12.1 + 1.2 + 10 + 9.4 = 32.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Astec Lifesciences compared with? Astec Lifesciences ranks 24 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 32.7 out of 100. 1. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) SHARDACROP · basing · Most evidence points up · 100% evidence 71.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidence Capital efficiency 19.5/25 · ROCE 30.2% · Operating margin 16% · 100% evidence Valuation 19.2/20 · P/E 9.3× · PEG 0.3 · 100% evidence Relative strength 4.6/20 · Lead over its industry -14.3% · Lead over NIFTY 500 -22.1% · 1 year -23.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28.5 + 19.5 + 19.2 + 4.6 = 71.8 · What this means: Earnings are strong; relative strength in its sector is -14.3% and the one-year return is -23.1%. 2. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) turning · Most evidence points up · 83% evidence 70.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.1/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 2 points · 83% evidence Capital efficiency 20.2/25 · ROCE 22.8% · Operating margin 21% · 95% evidence Valuation 5.4/20 · P/E 51.8× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 38.3% · Lead over NIFTY 500 25.1% · 1 year 101.5% · 100% evidence · 4 of 12 weeks ahead Exact sum: 28.1 + 20.2 + 5.4 + 16.7 = 70.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) BAYERCROP · quiet · Evidence leans up · 81% evidence 63.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue -2.8% · Profit 23.8% · Operating margin change 2 points · 88% evidence Capital efficiency 19.6/25 · ROCE 29.1% · Operating margin 20% · 100% evidence Valuation 13.4/20 · P/E 20× · PEG 1.28 · 100% evidence Relative strength 8.6/20 · Lead over its industry n/a · Lead over NIFTY 500 -20.8% · 1 year -33.3% · 25% evidence · 0 of 12 weeks ahead Exact sum: 22.3 + 19.6 + 13.4 + 8.6 = 63.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) PUNJABCHEM · quiet · Evidence leans up · 81% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 8.2% · Profit 43.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.6/25 · ROCE 18.6% · Operating margin 12% · 100% evidence Valuation 15.9/20 · P/E 17.4× · PEG 0.33 · 100% evidence Relative strength 9.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -9.4% · 1 year -36.4% · 25% evidence · 6 of 12 weeks ahead Exact sum: 24.3 + 13.6 + 15.9 + 9.8 = 63.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) DHARMAJ · losing its lead · Evidence leans up · 81% evidence 63.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 8.7% · Profit 13.2% · Operating margin change 1 points · 88% evidence Capital efficiency 14.7/25 · ROCE 16.8% · Operating margin 15% · 100% evidence Valuation 17.5/20 · P/E 14.3× · PEG 0.38 · 100% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 4.7% · 1 year -9.9% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.8 + 14.7 + 17.5 + 12.2 = 63.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) IPL · quiet · Evidence leans up · 81% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Revenue 17% · Profit 10.1% · Operating margin change -2 points · 88% evidence Capital efficiency 15.4/25 · ROCE 16.6% · Operating margin 14% · 100% evidence Valuation 18.2/20 · P/E 12× · PEG 0.36 · 100% evidence Relative strength 8.2/20 · Lead over its industry n/a · Lead over NIFTY 500 -23% · 1 year -40.7% · 25% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 15.4 + 18.2 + 8.2 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Advance Agrolife Ltd](https://www.sectoralpha.in/stocks/advance-agrolife-ltd) ADVANCE · breaking out · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.1/35 · Revenue 48.4% · Profit 81.5% · Operating margin change 1 points · 88% evidence Capital efficiency 14.1/25 · ROCE 19.6% · Operating margin 11% · 100% evidence Valuation 10.3/20 · P/E 16.3× · PEG n/a · 15% evidence Relative strength 12.4/20 · Lead over its industry n/a · Lead over NIFTY 500 10.6% · 1 year -8.6% · 25% evidence · 12 of 12 weeks ahead Exact sum: 22.1 + 14.1 + 10.3 + 12.4 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) DHANUKA · turning · Evidence leans up · 100% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidence Capital efficiency 19.6/25 · ROCE 25.9% · Operating margin 23% · 100% evidence Valuation 9.2/20 · P/E 14.4× · PEG 2.27 · 100% evidence Relative strength 17.4/20 · Lead over its industry 7.1% · Lead over NIFTY 500 -2.8% · 1 year -28.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10.8 + 19.6 + 9.2 + 17.4 = 57 · What this means: Relative strength against the index is -2.8%, and revenue and profit growth are weak. 9. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) JUBLINGREA · quiet · Evidence leans up · 93% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidence Capital efficiency 13.6/25 · ROCE 11.4% · Operating margin 15% · 100% evidence Valuation 6.7/20 · P/E 24.7× · PEG 2.26 · 65% evidence Relative strength 8.4/20 · Lead over its industry -2.6% · Lead over NIFTY 500 -11.7% · 1 year -19.1% · 100% evidence · 3 of 12 weeks ahead Exact sum: 26 + 13.6 + 6.7 + 8.4 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) MOL · breaking out · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue -7.8% · Profit 100% · Operating margin change 7 points · 88% evidence Capital efficiency 9.5/25 · ROCE 6.7% · Operating margin 18% · 100% evidence Valuation 9.6/20 · P/E 20.8× · PEG n/a · 15% evidence Relative strength 11.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.5% · 1 year -35% · 25% evidence · 11 of 12 weeks ahead Exact sum: 22 + 9.5 + 9.6 + 11 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) GSPCROP · quiet · Too little evidence to rank firmly · 59% evidence 51.0 out of 100 Growth Capital Valuation Relative
12. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) EPIGRAL · quiet · Evidence leans down · 81% evidence 49.6 out of 100 Growth Capital Valuation Relative
13. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) RALLIS · quiet · Evidence leans down · 85% evidence 48.4 out of 100 Growth Capital Valuation Relative
14. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) BHARATRAS · quiet · Evidence leans down · 96% evidence 45.3 out of 100 Growth Capital Valuation Relative
15. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) BHAGCHEM · quiet · Evidence leans down · 96% evidence 44.7 out of 100 Growth Capital Valuation Relative
16. [Shivalik Rasayan Ltd](https://www.sectoralpha.in/stocks/shivalik-rasayan-ltd) SHIVALIK · Evidence leans down · 63% evidence 43.9 out of 100 Growth Capital Valuation Relative
17. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) EXCELINDUS · quiet · Evidence leans down · 64% evidence 42.7 out of 100 Growth Capital Valuation Relative
18. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) NACLIND · basing · Evidence leans down · 96% evidence 42.0 out of 100 Growth Capital Valuation Relative
19. [Best Agrolife Ltd](https://www.sectoralpha.in/stocks/best-agrolife-ltd) BESTAGRO · quiet · Evidence leans down · 90% evidence 42.0 out of 100 Growth Capital Valuation Relative
20. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) SUMICHEM · quiet · Evidence leans down · 85% evidence 41.7 out of 100 Growth Capital Valuation Relative
21. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) UPL · basing · Evidence leans down · 71% evidence 41.5 out of 100 Growth Capital Valuation Relative
22. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) INSECTICID · quiet · Evidence leans down · 96% evidence 40.5 out of 100 Growth Capital Valuation Relative
23. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) PIIND · quiet · Evidence leans down · 81% evidence 38.3 out of 100 Growth Capital Valuation Relative
24. Astec Lifesciences Ltd this page ASTEC · quiet · Most evidence points down · 71% evidence 32.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.1/35 · Revenue 16.1% · Profit 29.2% · Operating margin change -18 points · 74% evidence Capital efficiency 1.2/25 · ROCE -5.4% · Operating margin -27% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 9.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 -15.2% · 1 year -17.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 12.1 + 1.2 + 10 + 9.4 = 32.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 25. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) HERANBA · quiet · Most evidence points down · 76% evidence 29.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pesticides/Agrochemicals](https://www.sectoralpha.in/sectors/pesticides-agrochemicals), all 25 compared on one page. ## Which companies are close to Astec Lifesciences in size? Astec Lifesciences is the 18th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Insecticides India, Meghmani Organics and India Pesticides. Just below it: Punjab Chemicals & Crop Protection, Excel Industries and Dharmaj Crop Guard. ### Pesticides/Agrochemicals companies close in size

1. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) ₹1,511 crore
2. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) ₹1,339 crore
3. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) ₹1,297 crore
4. Astec Lifesciences Ltd ₹1,216 crore
5. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) ₹1,166 crore
6. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) ₹1,074 crore
7. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) ₹862 crore

[All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies)

### Companies close in size in other industries

1. [Belding India Ltd](https://www.sectoralpha.in/stocks/belding-india-ltd) ₹1,221 crore · Aluminium
2. [Steel Exchange India Ltd](https://www.sectoralpha.in/stocks/steel-exchange-india-ltd) ₹1,221 crore · Steel Products
3. Astec Lifesciences Ltd ₹1,216 crore
4. [Platinum Industries Ltd](https://www.sectoralpha.in/stocks/platinum-industries-ltd) ₹1,215 crore · Speciality Chemicals
5. [Spice Lounge Food Works Ltd](https://www.sectoralpha.in/stocks/spice-lounge-food-works-ltd) ₹1,212 crore · Finance & Investments - Others

## What else do people ask about Astec Lifesciences? ### What is Astec Lifesciences's share price today? Astec Lifesciences Ltd's share price is ₹555.95, −15.8% over the past year. The whole company is worth ₹1,238 Cr on the market. In the last 52 weeks it traded between ₹543 to ₹838; today it is 4% of the way up from the low, 19.3% below its 200-day average (as of 3 November 2026). ### What were Astec Lifesciences's latest quarterly results? Astec Lifesciences Ltd reported revenue of ₹72.0 Cr and a net loss of ₹37.0 Cr for the Sep 2026 quarter. Earnings per share were −₹16.79. The operating margin was −27.0%, 18.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Astec Lifesciences's market cap? Astec Lifesciences Ltd's market capitalisation is ₹1,238 Cr at a share price of ₹555.95. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Astec Lifesciences performing? Astec Lifesciences Ltd's share price has been falling for 12 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Astec Lifesciences's share price go up? This page does not forecast Astec Lifesciences Ltd's share price. What it shows instead: the share price is ₹555.95, and it has been falling for 12 weeks. Its P/E of 110.6× is higher than 94% of its own last 7 years (as of 3 November 2026). ### Who owns Astec Lifesciences? Promoters own 72.0% of Astec Lifesciences Ltd, foreign institutions 0.0%, domestic institutions 3.3% and the public 24.7% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 5.2 percentage points over 8 quarters (as of 3 November 2026). ### Does Astec Lifesciences have too much debt? Yes, Astec Lifesciences Ltd has a lot of debt: its debt is 1.15× its equity, and its operating profit is 0 times its interest bill. FY26 borrowings were ₹449 Cr against equity of ₹390 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Astec Lifesciences in its business cycle? Astec Lifesciences Ltd's FY26 operating margin was −1.0%, against a 13-year range of −17.0% to 23.0%: the middle of its own range, neither a peak nor a low. The latest quarter was −27.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Astec Lifesciences story? The main question: promoters moved +5.2 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Astec Lifesciences a stock worth studying right now? What the numbers show: Astec Lifesciences Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.